Hagens Berman Sobol Shapiro LLP has issued a notice regarding a securities fraud class action lawsuit against Capricor Therapeutics, Inc., with a lead plaintiff application deadline of September 28, 2026. The lawsuit, filed in the Southern District of California, alleges that Capricor and certain executives made materially false and misleading statements about clinical trial data and the regulatory pathway for its lead product candidate Deramiocel, intended to treat Duchenne muscular dystrophy. Specifically, the complaint claims the company failed to disclose that it adopted changes to the pre-specified statistical analysis plan without agreement from the FDA prior to resubmitting its Biologics License Application. The class period runs from December 17, 2025 through July 26, 2026, during which Capricor's stock price rose 370% on December 3, 2025 after positive Phase 3 trial results were announced, then fell 64% on July 27, 2026 after an FDA briefing document revealed the study did not meet its pre-specified primary and secondary efficacy endpoints and that multiple SAP versions were generated. Investors who suffered substantial losses are encouraged to contact the firm to discuss potential recoveries and lead plaintiff rights.
